NCT03249103: A trial that was reported late by Aptinyx
This trial has reported, although it was 533 days late in doing so.
Full data
| Full entry on ClinicalTrials.gov | NCT03249103 |
|---|---|
| Title | A Phase 2, Single-Blind, Exploratory, Placebo-controlled, Pilot Study to Assess the Efficacy and Safety of Daily Oral NYX-2925 in Subjects With Fibromyalgia |
| Results Status | Reported (late) |
| ACT or pACT? | This is what FDAAA officially calls an "Applicable Clinical Trial" |
| Start date | Aug. 14, 2017 |
| Completion date | April 18, 2019 |
| Required reporting date | April 17, 2020, midnight |
| Actual reporting date | Oct. 3, 2021 |
| Date last checked at ClinicalTrials.gov | Dec. 12, 2025 |
| Days late | 533 |